159 related articles for article (PubMed ID: 28748626)
1. Combining "Bottom-up" and "Top-down" Approaches to Assess the Impact of Food and Gastric pH on Pictilisib (GDC-0941) Pharmacokinetics.
Lu T; Fraczkiewicz G; Salphati L; Budha N; Dalziel G; Smelick GS; Morrissey KM; Davis JD; Jin JY; Ware JA
CPT Pharmacometrics Syst Pharmacol; 2017 Nov; 6(11):747-755. PubMed ID: 28748626
[TBL] [Abstract][Full Text] [Related]
2. Impact of food and the proton pump inhibitor rabeprazole on the pharmacokinetics of GDC-0941 in healthy volunteers: bench to bedside investigation of pH-dependent solubility.
Ware JA; Dalziel G; Jin JY; Pellett JD; Smelick GS; West DA; Salphati L; Ding X; Sutton R; Fridyland J; Dresser MJ; Morrisson G; Holden SN
Mol Pharm; 2013 Nov; 10(11):4074-81. PubMed ID: 24099279
[TBL] [Abstract][Full Text] [Related]
3. Use of Physiologically Based Pharmacokinetic Modeling for Predicting Drug-Food Interactions: Recommendations for Improving Predictive Performance of Low Confidence Food Effect Models.
Wagner C; Kesisoglou F; Pepin XJH; Parrott N; Emami Riedmaier A
AAPS J; 2021 Jun; 23(4):85. PubMed ID: 34142242
[TBL] [Abstract][Full Text] [Related]
4. A Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of Pictilisib in Combination with Erlotinib in Patients with Advanced Solid Tumors.
Leong S; Moss RA; Bowles DW; Ware JA; Zhou J; Spoerke JM; Lackner MR; Shankar G; Schutzman JL; van der Noll R; Voest EE; Schellens JHM
Oncologist; 2017 Dec; 22(12):1491-1499. PubMed ID: 28798270
[TBL] [Abstract][Full Text] [Related]
5. Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors.
Shapiro GI; LoRusso P; Kwak E; Pandya S; Rudin CM; Kurkjian C; Cleary JM; Pilat MJ; Jones S; de Crespigny A; Fredrickson J; Musib L; Yan Y; Wongchenko M; Hsieh HJ; Gates MR; Chan IT; Bendell J
Invest New Drugs; 2020 Apr; 38(2):419-432. PubMed ID: 31020608
[TBL] [Abstract][Full Text] [Related]
6. First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors.
Sarker D; Ang JE; Baird R; Kristeleit R; Shah K; Moreno V; Clarke PA; Raynaud FI; Levy G; Ware JA; Mazina K; Lin R; Wu J; Fredrickson J; Spoerke JM; Lackner MR; Yan Y; Friedman LS; Kaye SB; Derynck MK; Workman P; de Bono JS
Clin Cancer Res; 2015 Jan; 21(1):77-86. PubMed ID: 25370471
[TBL] [Abstract][Full Text] [Related]
7. A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non-small cell lung cancer.
Soria JC; Adjei AA; Bahleda R; Besse B; Ferte C; Planchard D; Zhou J; Ware J; Morrissey K; Shankar G; Lin W; Schutzman JL; Dy GK; Groen HJM
Eur J Cancer; 2017 Nov; 86():186-196. PubMed ID: 28992562
[TBL] [Abstract][Full Text] [Related]
8. Effect of Microenvironmental pH Modulation on the Dissolution Rate and Oral Absorption of the Salt of a Weak Acid - Case Study of GDC-0810.
Hou HH; Jia W; Liu L; Cheeti S; Li J; Nauka E; Nagapudi K
Pharm Res; 2018 Jan; 35(2):37. PubMed ID: 29380076
[TBL] [Abstract][Full Text] [Related]
9. Physiologically Based Pharmacokinetic Modeling of Oral Absorption, pH, and Food Effect in Healthy Volunteers to Drive Alpelisib Formulation Selection.
Gajewska M; Blumenstein L; Kourentas A; Mueller-Zsigmondy M; Lorenzo S; Sinn A; Velinova M; Heimbach T
AAPS J; 2020 Oct; 22(6):134. PubMed ID: 33070288
[TBL] [Abstract][Full Text] [Related]
10. Bioequivalence of a Newly Developed Dabigatran Etexilate Tablet Versus the Commercial Capsule and Impact of Rabeprazole-Induced Elevated Gastric pH on Exposure in Healthy Subjects.
Harada A; Ikushima I; Haranaka M; Yanagihara A; Nakayama D
Am J Cardiovasc Drugs; 2020 Jun; 20(3):249-258. PubMed ID: 31667735
[TBL] [Abstract][Full Text] [Related]
11. Physiologically Based Absorption Modelling to Explore the Impact of Food and Gastric pH Changes on the Pharmacokinetics of Entrectinib.
Parrott N; Stillhart C; Lindenberg M; Wagner B; Kowalski K; Guerini E; Djebli N; Meneses-Lorente G
AAPS J; 2020 May; 22(4):78. PubMed ID: 32458089
[TBL] [Abstract][Full Text] [Related]
12.
Han N; Jiang Y; Gai Y; Liu Q; Yuan L; Wang Y; Li M; Zhang Y; Lan X
Contrast Media Mol Imaging; 2019; 2019():1760184. PubMed ID: 31787861
[TBL] [Abstract][Full Text] [Related]
13. Phase Ia/Ib study of the pan-class I PI3K inhibitor pictilisib (GDC-0941) administered as a single agent in Japanese patients with solid tumors and in combination in Japanese patients with non-squamous non-small cell lung cancer.
Yamamoto N; Fujiwara Y; Tamura K; Kondo S; Iwasa S; Tanabe Y; Horiike A; Yanagitani N; Kitazono S; Inatani M; Tanaka J; Nishio M
Invest New Drugs; 2017 Feb; 35(1):37-46. PubMed ID: 27565810
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and absorption of the anticancer agents dasatinib and GDC-0941 under various gastric conditions in dogs--reversing the effect of elevated gastric pH with betaine HCl.
Pang J; Dalziel G; Dean B; Ware JA; Salphati L
Mol Pharm; 2013 Nov; 10(11):4024-31. PubMed ID: 23980865
[TBL] [Abstract][Full Text] [Related]
15. Randomised trial of acid inhibition by vonoprazan 10/20 mg once daily vs rabeprazole 10/20 mg twice daily in healthy Japanese volunteers (SAMURAI pH study).
Takeuchi T; Furuta T; Fujiwara Y; Sugimoto M; Kasugai K; Kusano M; Okada H; Suzuki T; Higuchi T; Kagami T; Uotani T; Yamade M; Sawada A; Tanaka F; Harada S; Ota K; Kojima Y; Murata M; Tamura Y; Funaki Y; Kawamura O; Okamoto Y; Fujimoto K; Higuchi K
Aliment Pharmacol Ther; 2020 Mar; 51(5):534-543. PubMed ID: 31990424
[TBL] [Abstract][Full Text] [Related]
16. The impact of a 1-hour time interval between pazopanib and subsequent intake of gastric acid suppressants on pazopanib exposure.
Krens SD; Lubberman FJE; van Egmond M; Jansman FGA; Burger DM; Hamberg P; Vervenne WL; Gelderblom H; van der Graaf WTA; Desar IME; van Herpen CML; van Erp NP
Int J Cancer; 2021 Jun; 148(11):2799-2806. PubMed ID: 33428771
[TBL] [Abstract][Full Text] [Related]
17. Distribution of the phosphatidylinositol 3-kinase inhibitors Pictilisib (GDC-0941) and GNE-317 in U87 and GS2 intracranial glioblastoma models-assessment by matrix-assisted laser desorption ionization imaging.
Salphati L; Shahidi-Latham S; Quiason C; Barck K; Nishimura M; Alicke B; Pang J; Carano RA; Olivero AG; Phillips HS
Drug Metab Dispos; 2014 Jul; 42(7):1110-6. PubMed ID: 24754926
[TBL] [Abstract][Full Text] [Related]
18. Negative Food Effect of Danirixin: Use of PBPK Modelling to Explore the Effect of Formulation and Meal Type on Clinical PK.
Lloyd RS; Hingle MI; Bloomer JC; Charles SJ; Butler JM; Paul A; Zhu X; Miller B; D'Amico D; Donald A; Tal-Singer R; Ambery C
Pharm Res; 2020 Oct; 37(12):233. PubMed ID: 33123802
[TBL] [Abstract][Full Text] [Related]
19. Ribociclib Bioavailability Is Not Affected by Gastric pH Changes or Food Intake: In Silico and Clinical Evaluations.
Samant TS; Dhuria S; Lu Y; Laisney M; Yang S; Grandeury A; Mueller-Zsigmondy M; Umehara K; Huth F; Miller M; Germa C; Elmeliegy M
Clin Pharmacol Ther; 2018 Aug; 104(2):374-383. PubMed ID: 29134635
[TBL] [Abstract][Full Text] [Related]
20. Phase 1 Study Evaluating the Effects of the Proton Pump Inhibitor Rabeprazole and Food on the Pharmacokinetics of Lorlatinib in Healthy Participants.
Xu H; O'Gorman MT; Nepal S; James LP; Ginman K; Pithavala YK
Clin Pharmacol Drug Dev; 2021 Nov; 10(11):1395-1404. PubMed ID: 34288547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
